Clinical Trials
18 trialsNCT05717140 2025-08-07
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Mayo Clinic
Phase 1 Withdrawn
NCT03167177 2025-02-21
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
ImmunityBio, Inc.
Phase 1/2 Withdrawn
NCT05496192 2023-04-14
A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT04891718 2022-07-08
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
Phase EARLY_PHASE1 Withdrawn
NCT04955262 2021-07-08
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
Nektar Therapeutics
Phase 1 Withdrawn
NCT04060407 2021-06-01
CINDI
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2 Withdrawn
NCT04042506 2021-04-12
SBRT as a Vaccination for Metastatic Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT04495010 2021-03-19
CheckMate 7UA
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03758729 2021-02-16
Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.
Samsung Medical Center
Phase 2 Withdrawn
NCT03126461 2020-08-20
SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT04125719 2020-02-11
PPD1
Duke University
Phase 1 Withdrawn
NCT04007588 2020-02-05
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT03767439 2019-12-18
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Columbia University
Phase 2 Withdrawn
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT03326258 2018-07-18
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT02736123 2017-09-20
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
University of Pittsburgh
Phase 1/2 Withdrawn
NCT02400385 2017-02-01
A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma
California Pacific Medical Center Research Institute
Phase 2 Withdrawn
NCT02357732 2015-12-11
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
University of Pittsburgh
Phase 1 Withdrawn